FULT vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FULT presents a stark contrast between deep value and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the stock trades at a significant discount to both its Graham Number ($29.29) and Intrinsic Value ($61.36), the bearish technical trend and insider selling suggest caution. Strong earnings growth (46.5% YoY) and a consistent track record of beating estimates provide a bullish counter-narrative, but the low health score indicates underlying operational or financial instability. Overall, it is a high-value play with concerning health metrics.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
FULT vs JPM: Head-to-Head Comparison
This page compares Fulton Financial Corporation (FULT) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.